Alliancebernstein L.P. Sells 9,760 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Alliancebernstein L.P. trimmed its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 2.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 445,028 shares of the biotechnology company’s stock after selling 9,760 shares during the quarter. Alliancebernstein L.P. owned about 0.73% of Ascendis Pharma A/S worth $61,267,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Zimmer Partners LP bought a new position in shares of Ascendis Pharma A/S in the third quarter worth about $11,646,000. XTX Topco Ltd acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $1,692,000. Main Management ETF Advisors LLC bought a new position in Ascendis Pharma A/S in the 3rd quarter worth approximately $927,000. Y Intercept Hong Kong Ltd acquired a new position in Ascendis Pharma A/S during the 3rd quarter worth $886,000. Finally, Nomura Asset Management Co. Ltd. boosted its position in Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock valued at $2,688,000 after buying an additional 5,371 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Cantor Fitzgerald upped their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price on the stock. Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average target price of $204.64.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $142.67 on Friday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The company has a market capitalization of $8.66 billion, a P/E ratio of -20.09 and a beta of 0.61. The business has a 50-day moving average of $146.39 and a two-hundred day moving average of $138.07.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. On average, equities analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.